Advertising and Promotion Approval: Articles 44-47 and Validity from 30 Days to 1 Year

1. Key takeaways

Articles 44-47 provide that the advertising and promotion of medical products must be approved by EDE, and Article 46 allows the applicant to choose a validity period anywhere from 30 days to 1 year. Our judgment is that advertising approval in the UAE is a third permit, independent of product registration; obtaining a marketing authorization does not mean the product may be promoted. The design of a validity period chosen by the applicant in effect hands the scheduling responsibility to the company. The reason is that Article 46 grants the choice and the approval lapses on expiry; a company can no longer rely on being in the approval process as grounds for continuing to advertise. On the trade-off, back-plan the approval application from the promotion plan instead of defaulting to 1 year.

• Articles 44-47: advertising and promotion of medical products require EDE approval, as a permit independent of registration.
• Article 46 lets the applicant choose the validity period between 30 days and 1 year; the approval lapses on expiry.
• Article 5 prohibits import, distribution, holding, sale, display, re-marketing, use or production without a marketing authorization.
• Advertising content must be consistent with the approved labeling and instructions for use, or it triggers review under both Articles 44-47 and Article 6(1)(g).

2. Legal basis

The articles constituting the advertising approval regime, and Article 5 which frames the underlying prohibition, are set out in the table below.

3. Expert insights

Insight 1: Advertising approval is independent of the marketing authorization; promoting before approval is a separate violation. Our professional judgment is that managing promotion as something bundled with product registration will miss this link. The reason is that Article 5 lists display among the prohibited acts when there is no marketing authorization, while Articles 44-47 separately require advertising and promotion to be approved by EDE; the two provisions stand in a progressive relationship. On the trade-off, advertising approval should be placed on the pre-market parallel checklist and advanced in step with the registration application, rather than started only after the certificate is granted; otherwise the product is saleable but cannot be promoted.

Insight 2: A self-chosen validity of 30 days to 1 year: short cycles are more economical but costlier to manage. The judgment is that the validity period should be decided by the placement plan, not set to the maximum in every case. The reason is that Article 46 hands the choice to the applicant, which at the same time means a new application is required after expiry. On the trade-off, choose 30 days for short campaigns and 1 year for long-term brand presence; we do not recommend occupying a long-cycle approval for a single exhibition or one quarter’s activity, nor repeatedly applying for short permits for long-term placement.

Insight 3: Advertising content must be consistent with the approved labeling and instructions for use. The judgment is that promotion beyond the approved indications or intended use triggers review under both Articles 44-47 and Article 6(1)(g). The reason is that item (g) requires the inner and outer packaging and the paper or electronic instructions for use to provide the product’s full information and to comply with the EDE labeling guidance; if the advertising copy is inconsistent with it, unregistered information has effectively been made public. On the trade-off, the approved instructions for use are the sole source of advertising copy, and extension of the wording by the marketing department is not permitted.

4. Practical recommendations

• Place advertising approval on the pre-market parallel checklist and advance it in step with the registration application, so that the product is not saleable but unpromotable.
• Choose the validity period by the placement plan: 30 days for short campaigns, 1 year for long-term brand placement, with expiry reminders set.
• Use the approved Arabic and English instructions for use as the sole source of advertising copy; extension of indications and intended use wording is prohibited.
• Bring all promotional materials, including exhibition materials, digital media content and sample catalogs provided to distributors, within the scope of approval, with no exceptions.
• Agree with the responsible entity on the division of tasks and deadlines for submitting promotional materials for approval; distributor self-made materials must be reviewed by the rights holder before submission to EDE.
• Archive advertising approval documents by placement channel, complete placement within the approved validity period, and do not renew placement of approvals that expire unused.

5. Verification checklist

• □ Advertising approval is on the pre-market parallel checklist, advanced in step with the registration application
• □ The validity period has been chosen by the placement plan, with the expiry date of the 30 days or 1 year choice recorded in the ledger
• □ Advertising copy has been checked sentence by sentence against the approved instructions for use, with no extended wording
• □ Exhibition materials, digital media content and distributor sample catalogs are all within the scope of approval
• □ The division of tasks and deadlines for submitting promotional materials are written into the agreement with the responsible entity
• □ Advertising approval documents are archived by channel, and placement is completed within the validity period
• □ Display and sale under Article 5 are verified in linkage with the status of advertising approval

Further reading: Article No. 47, The Pricing Mechanism and the Drug Policy Committee: Article 36 and Ministerial Decision No. 130/2019; Article No. 48, Penalties and Appeals: Articles 160, 162 and 168 and the AED 1,000-1,000,000 Range; Article No. 6, The Mandatory Nature of the Marketing Authorization: The Red Lines of Article 5 and Two Categories of Exemption.

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages adverse event reporting and recall coordination with MOHAP, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com